NCT07784959 Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
| NCT ID | NCT07784959 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Nuvectis Pharma, Inc. |
| Condition | ALK Positive |
| Study Type | INTERVENTIONAL |
| Enrollment | 54 participants |
| Start Date | 2026-08-17 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 54 participants in total. It began in 2026-08-17 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)
Eligibility Criteria
Inclusion Criteria: * 18 years old or older * Unresectable, metastatic or locally advanced ALK-positive NSCLC. * Must have received lorlatinib as first or second line TKI * One prior line of systemic chemotherapy is permitted * Must have tolerated the dose level of lorlatinib actively being explored in the study or a higher dose Exclusion Criteria: * Known single or compound ALK domain mutations that cause resistance to lorlatinib, or known actionable oncogenic driver alterations other than ALK with approved targeted therapies available, such as, MET or EGFR mutations or HER2 overexpression * Any contraindications to treatment with lorlatinib according to the lorlatinib United States Prescribing Information (USPI)
Contact & Investigator
Christine Lovly, MD, PhD
PRINCIPAL INVESTIGATOR
City of Hope Medical Center
Frequently Asked Questions
Who can join the NCT07784959 clinical trial?
This trial is open to participants of all sexes, studying ALK Positive. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07784959 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07784959 currently recruiting?
Yes, NCT07784959 is actively recruiting participants. Contact the research team at ebelshaw@nuvectis.com for enrollment information.
Where is the NCT07784959 trial being conducted?
This trial is being conducted at Fairfax, United States.
Who is sponsoring the NCT07784959 clinical trial?
NCT07784959 is sponsored by Nuvectis Pharma, Inc.. The principal investigator is Christine Lovly, MD, PhD at City of Hope Medical Center. The trial plans to enroll 54 participants.